A novel proprietary molecular technology platform
ABOUT
We aim to develop proprietary molecular detection technologies deploying ultra-rapid isothermal nucleic acid amplification that enable near-patient and at-home testing for infectious disease or genetic indications.
We are committed to producing diagnostic devices that will provide rapid sample to answer solutions where they are most needed.
We will accomplish this by developing products under the framework of a continually improved quality system:
- That is compliant with regulatory requirements
- By treating our customers, partners, and suppliers in a fair and ethical manner
- Providing the necessary support to our staff so that they can undertake the tasks required of them.
REVOLUTIONARY PRODUCTS
Biocrucible’s technology can significantly improve the performance of many processes already currently in use throughout the life science and diagnostic industries, and we anticipate novel applications as well.
Molecular Diagnostics
Biocrucible is developing a class-leading molecular diagnostic platform based on its proprietary isothermal nucleic acid amplification technology that is ideally suited to consumer and developing-world applications.
OUR VALUES
We Innovate Together
We Care for
Each Other
We Deliver on our commitments
Individually and as a team we focus on creating value for our customers, investors and partners
OUR PARTNERS
Advanced testing capabilities
With multiple technologies for detection we have the right detection technology for each test and healthcare setting.
KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions.
Sapphiros Laboratories is CLIA certified and operates on a national scale with comprehensive clinical and digital solutions to provide a seamless collection, testing and reporting solution.
neoenta design is a partner in innovation—with a hands-on approach to bringing new technologies to life through careful development, cultivation and incubation.
GoToKnow™ is a direct to consumer sales channel that empowers you to take charge of your health through a portfolio of diagnostic tests, and your wellness through a suite of wellness-focused genomic tests.
Flexotronix has designed and developed an Extreme Volume Manufacturing process to manufacture innovative and proprietary lateral flow formats. The manufacturing line has a measured capacity of up to 5 billion tests per year.
The SatioPatch™ Platform provides consumer-based diagnosis through a convenient and simple to use patch utilizing a wide variety of technologies for an increasing demand for rapid, point of care diagnosis.